image
Healthcare - Medical - Instruments & Supplies - NASDAQ - IL
$ 0.3527
-2.35 %
$ 3.67 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GCTK stock under the worst case scenario is HIDDEN Compared to the current market price of 0.353 USD, GlucoTrack, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GCTK stock under the base case scenario is HIDDEN Compared to the current market price of 0.353 USD, GlucoTrack, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GCTK stock under the best case scenario is HIDDEN Compared to the current market price of 0.353 USD, GlucoTrack, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
0 REVENUE
0.00%
-7.1 M OPERATING INCOME
-60.29%
-7.1 M NET INCOME
-60.02%
-6.56 M OPERATING CASH FLOW
-75.86%
0 INVESTING CASH FLOW
0.00%
8.73 M FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
3.25 M OPERATING INCOME
172.39%
-5.09 M NET INCOME
-13.32%
-4.14 M OPERATING CASH FLOW
-117.20%
-33 K INVESTING CASH FLOW
-175.00%
4.38 M FINANCING CASH FLOW
655.17%
Balance Sheet GlucoTrack, Inc.
image
Current Assets 4.87 M
Cash & Short-Term Investments 4.49 M
Receivables 0
Other Current Assets 376 K
Non-Current Assets 37 K
Long-Term Investments 0
PP&E 27 K
Other Non-Current Assets 10 K
Current Liabilities 1.51 M
Accounts Payable 839 K
Short-Term Debt 0
Other Current Liabilities 673 K
Non-Current Liabilities 196 K
Long-Term Debt 196 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall GlucoTrack, Inc.
image
Revenue 0
Cost Of Revenue 13 K
Gross Profit -13 K
Operating Expenses 7.1 M
Operating Income -7.1 M
Other Expenses -7 K
Net Income -7.1 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-221.99% ROE
-221.99%
-144.69% ROA
-144.69%
-209.37% ROIC
-209.37%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis GlucoTrack, Inc.
image
Net Income -7.1 M
Depreciation & Amortization 13 K
Capital Expenditures 0
Stock-Based Compensation 281 K
Change in Working Capital 190 K
Others 78 K
Free Cash Flow -6.56 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets GlucoTrack, Inc.
image
GCTK has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership GlucoTrack, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
891 K USD 2
6-9 MONTHS
230 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
8 months ago
Jul 01, 2024
Bought 683 K USD
SYCOFF DREW
director, 10 percent owner:
+ 138000
4.95 USD
8 months ago
Jul 01, 2024
Bought 208 K USD
Goode Paul
Chief Executive Officer
+ 42000
4.95 USD
10 months ago
Apr 22, 2024
Bought 230 K USD
SYCOFF DREW
director, 10 percent owner:
+ 182539.6
1.26 USD
7 years ago
Mar 08, 2017
Bought 1 M USD
Darivoff Philip
Director
+ 222223
4.5 USD
7 years ago
Mar 08, 2017
Bought 1.72 M USD
Darivoff Philip
Director
+ 222223
7.75 USD
7 years ago
Mar 08, 2017
Bought 4.5 K USD
Darivoff Philip
Director
+ 1000
4.5 USD
8 years ago
Nov 30, 2016
Bought 517 K USD
Darivoff Philip
Director
+ 66667
7.75 USD
8 years ago
Nov 30, 2016
Bought 300 K USD
Darivoff Philip
Director
+ 66667
4.5 USD
8 years ago
Nov 30, 2016
Bought 1.35 K USD
Darivoff Philip
Director
+ 300
4.5 USD
7. News
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 3 weeks ago
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor The study met its primary endpoint with no procedure or device related serious adverse events reported The study met its primary endpoint with no procedure or device related serious adverse events reported globenewswire.com - 3 weeks ago
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes globenewswire.com - 1 month ago
Glucotrack Announces ISO 13485:2016 Certification ISO Certification highlights commitment to quality for continuous blood glucose monitor ISO Certification highlights commitment to quality for continuous blood glucose monitor globenewswire.com - 1 month ago
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes globenewswire.com - 1 month ago
Glucotrack to Present at TechBio Showcase™ 2025 Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes globenewswire.com - 1 month ago
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR Feasibility study underway for the Company's novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks globenewswire.com - 2 months ago
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the closing of a “best efforts” public offering of 2,437,340 shares of common stock and 4,756,900 pre-funded warrants, with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share. The combined offering price of each share of common stock together with the accompanying series A and series B common warrants is $1.39, and the combined offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $1.389. The gross proceeds of the public offering were approximately $10 million before deducting placement agent fees and offering expenses. globenewswire.com - 3 months ago
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the 2024 BioFuture Conference, to be held at Cure in New York City from October 28-30, 2024. Paul V. Goode, President & Chief Executive Officer of Glucotrack, will present on Tuesday, October 29, 2024, at 11:00 AM ET and will hold one-on-one meetings. globenewswire.com - 4 months ago
GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference globenewswire.com - 5 months ago
JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes globenewswire.com - 5 months ago
8. Profile Summary

GlucoTrack, Inc. GCTK

image
COUNTRY IL
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 3.67 M
Dividend Yield 0.00%
Description GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Contact 8 Ariel Sharon Street, Or Yehuda, 7760049 https://www.glucotrack.com
IPO Date April 25, 2013
Employees 6
Officers Mr. Avner Gal MBA, MSc.EE Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board Mr. Mark Tapsak Ph.D. Vice President of Technology Mr. Peter C. Wulff Chief Financial Officer Ms. Drinda Benjamin Vice President of Marketing Mr. Paul V. Goode Ph.D. Chief Executive Officer, President & Director Mr. Vincent Wong Vice President of Quality Mr. David Malka BA Co-Founder Mr. James P. Thrower Ph.D. Vice President of Engineering